Fortress Biotech Repaid Oaktree Credit Facility, Agreement Terminated

What Happened
Fortress Biotech, Inc. announced in an 8-K that it repaid in full the remaining debt under its $50.0 million senior secured credit agreement with Oaktree Fund Administration, LLC. The company made the final repayment on September 30, 2026, satisfying all outstanding indebtedness and triggering automatic termination of the Oaktree Agreement.

Key Details

• Original facility: $50.0 million senior secured credit agreement entered July 25, 2024 (amended Dec 12, 2025 and Feb 22, 2026).
• Final repayment on Sept 30, 2026: $15.0 million principal outstanding plus approximately $435,000 accrued interest.
• Additional costs: $150,000 prepayment fee and other closing costs.
• Consequence: All indebtedness deemed paid in full, and all liens and security interests securing the facility were released; the Oaktree Agreement automatically terminated.
• 8‑K filed Oct 1, 2026 and signed by David Jin, Chief Financial Officer.

Why It Matters
This action eliminates Fortress Biotech’s outstanding borrowings under the Oaktree facility and removes associated liens on the company’s assets. For investors, that means a reduction in reported debt and interest obligations tied to this facility and clear ownership of any previously encumbered assets. The filing is a material financing update rather than an earnings report or management change.